: 
Harold B. Reisman, "Economic Analysis of Fermentation Processes"
English | 2021 | ISBN: 0367206285 | PDF | pages: 246 | 17.8 mb
The last decade has been marked by enormous change in the life sciences. New bioactive entities have been made and novel techniques have opened new vistas in molecular biology. Monoclonal antibodies offer a reasonable hope for targeted drug missiles to cure disease; many new diagnostic methods are based on this advance. New vaccines are being prepared from specific protein moieties offering disease prevention without side effects. In microbiology, classic mutation methods have been superceded by protoplast fusion and recombinant DNA technology. A host of new compounds arises monthly and new processes are presented which offer potential for mass production of well-known biodynamic molecules as well as the ever-growing list of newer ones.
The more mundane area of economics (as applied to what is called, for simplicity, biotechnology) has only recently received more serious attention in the business community. Sooner or later, one must move from concept, discovery, or laboratory preparation to sale of a desired material. This simple fact is true regardless of the material's nature or its derivation. The many new biotechnology companies are finding that issuance of stock and even a patentable discovery are not sufficient to maintain long-term corporate viability. Many of these companies may find themselves in the position of creators, holders, or purveyors of technology while they are, or may become, totally dependent upon larger competitors (major pharmaceutical companies) to do actual production, marketing, and sale of resultant products.
Links are Interchangeable - No Password - Single Extraction